ES2118756T3 - Estimuladores de hematopoyesis de multiples dominios. - Google Patents

Estimuladores de hematopoyesis de multiples dominios.

Info

Publication number
ES2118756T3
ES2118756T3 ES91920109T ES91920109T ES2118756T3 ES 2118756 T3 ES2118756 T3 ES 2118756T3 ES 91920109 T ES91920109 T ES 91920109T ES 91920109 T ES91920109 T ES 91920109T ES 2118756 T3 ES2118756 T3 ES 2118756T3
Authority
ES
Spain
Prior art keywords
hematopoyesis
stimulators
multiple domain
domain
hematopoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920109T
Other languages
English (en)
Other versions
ES2118756T5 (es
Inventor
Paul Schendel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24298530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2118756(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of ES2118756T3 publication Critical patent/ES2118756T3/es
Application granted granted Critical
Publication of ES2118756T5 publication Critical patent/ES2118756T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE SUMINISTRAN NUEVAS PROTEINAS DE FUSION, IL3-X O X-IL3, EN DONDE X ES UNA LIMFOQUINA FUNDIDA AL IL3.
ES91920109T 1990-08-29 1991-08-29 Estimuladores de hematopoyesis de multiples dominios. Expired - Lifetime ES2118756T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57500390A 1990-08-29 1990-08-29
US575003 1990-08-29

Publications (2)

Publication Number Publication Date
ES2118756T3 true ES2118756T3 (es) 1998-10-01
ES2118756T5 ES2118756T5 (es) 2004-01-16

Family

ID=24298530

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920109T Expired - Lifetime ES2118756T5 (es) 1990-08-29 1991-08-29 Estimuladores de hematopoyesis de multiples dominios.

Country Status (11)

Country Link
US (1) US5883230A (es)
EP (1) EP0546124B2 (es)
JP (1) JP3149182B2 (es)
AT (1) ATE167896T1 (es)
AU (1) AU651152B2 (es)
CA (1) CA2089553C (es)
DE (1) DE69129697T3 (es)
DK (1) DK0546124T4 (es)
ES (1) ES2118756T5 (es)
GR (1) GR3027790T3 (es)
WO (1) WO1992004455A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
CA2069746A1 (en) * 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1995028427A1 (en) * 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
US5582821A (en) * 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
JPH11500308A (ja) 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
AU705064B2 (en) * 1995-04-26 1999-05-13 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptides
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6887461B1 (en) 1998-10-26 2005-05-03 Genetics Institute, Llc Method of using IL-11 for treating mucositis
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6884419B1 (en) 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
BR0012429A (pt) 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
EP1731531B1 (en) * 1999-08-09 2012-05-30 Merck Patent GmbH Multiple cytokine-antibody complexes
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
PL371781A1 (en) 2001-07-11 2005-06-27 Maxygen Holdings, Ltd. G-csf conjugates
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP1888119B1 (en) 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
LT6161B (lt) * 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
WO1985004420A1 (fr) * 1984-03-29 1985-10-10 Takeda Chemical Industries, Ltd. Nouvel adn et son utilisation
US4691009A (en) * 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
EP0205404B1 (en) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63267278A (ja) * 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体を暗号化する塩基配列
US5032395A (en) * 1986-07-14 1991-07-16 Genetics Institute, Inc. Method of inducing leukocytosis with a combination of IL-3 and GM-CSF
DE3751664T2 (de) * 1986-08-01 1996-06-05 Commw Scient Ind Res Org Rekombinanter impfstoff
EP0585957A1 (en) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
JPH082315B2 (ja) * 1987-05-29 1996-01-17 財団法人相模中央化学研究所 リンホトキシンを含む融合蛋白質
EP0425536A4 (en) * 1988-07-20 1992-01-02 Immunex Corporation Nonglycosylated human interleukin-3 compositions
US5217719A (en) * 1989-01-09 1993-06-08 Kao Corporation Surface-treated sodium bicarbonate particle and molded preparation thereof
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
CA2014473A1 (en) * 1989-04-14 1990-10-14 Hong-Ji Xu Purified, highly specific antibodies against gene products including retinoblastoma and method
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JPH04501808A (ja) * 1989-07-06 1992-04-02 セラジェン・インコーポレーテッド ハイブリッド分子
US5108910A (en) * 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
ES2055445T3 (es) * 1989-08-22 1994-08-16 Immunex Corp Proteinas de fusion que comprenden gm-csf e il-3.
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
CA2069746A1 (en) * 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors

Also Published As

Publication number Publication date
AU8917491A (en) 1992-03-30
GR3027790T3 (en) 1998-11-30
AU651152B2 (en) 1994-07-14
US5883230A (en) 1999-03-16
JP3149182B2 (ja) 2001-03-26
JPH06500116A (ja) 1994-01-06
DE69129697T3 (de) 2004-01-29
DE69129697T2 (de) 1999-01-07
ATE167896T1 (de) 1998-07-15
EP0546124B1 (en) 1998-07-01
WO1992004455A1 (en) 1992-03-19
DE69129697D1 (de) 1998-08-06
CA2089553A1 (en) 1992-03-01
EP0546124B2 (en) 2003-04-23
DK0546124T3 (da) 1998-10-26
ES2118756T5 (es) 2004-01-16
DK0546124T4 (da) 2003-05-19
CA2089553C (en) 2000-06-27
EP0546124A1 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
ES2118756T3 (es) Estimuladores de hematopoyesis de multiples dominios.
ES2024709B3 (es) Union de barras polioefinicas por fusion.
ES510011A0 (es) "un metodo de crear un microorganismo capaz de producir una proteina predeterminada por expresion".
SE9301270D0 (sv) Biosensor
DE69200447D1 (de) Erzeugung von russen.
DE69020141D1 (de) Verbesserte brillenhalterung.
FI841601A7 (fi) Prolin-derivat.
DE68916129D1 (de) Multifokale Diffraktionslinse.
DK378789D0 (da) Brille
DE68921432D1 (de) Brillenlinse.
BR9106584A (pt) Novo reometro de fusao em linha
FI923915A7 (fi) Paranettuja kimeerisiä toksiineja
IT1223738B (it) Occhiali
ES1013068Y (es) Cepillo de dientes.
DE69107164D1 (de) Synthesis von Ethylamine.
FI872788A7 (fi) Parannettuja fuusiotuotteita.
DE68922130D1 (de) Verwendung von 2-Methoxy-4-Propyl-1-Cyclohexanol als Duftstoff.
DK284489D0 (da) Fusionsproteiner
ES292706Y (es) Articulacion de gafas.
ES1008348Y (es) Portalamparas hecho de materia plastica.
DE59001080D1 (de) Brillenfassung.
ES1006993Y (es) Servilletero.
IT213048Z2 (it) Molla raschiatrice
ATE51874T1 (de) Prolin-derivate.
BR6801586U (pt) Prendedor de roupas jr.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 546124

Country of ref document: ES